Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins
NCT04690920
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Corona Virus Disease 2019 (COVID-19)
Interventions
DRUG:
Tocilizumab
Sponsor
University of Lahore